Abstract:Objective:To develop a polymeric drug delivery system for paclitaxel and determine whether paclitaxel nanoparticle can inhibit progressive growth of ovarian carcinoma in the peritoneal cavity of female F344 rat.Methods:Paclitaxel loading nanoparticle(PLA) synthesized.MTT analysis identified cytotoxic activity of paclitaxel nanoparticle in vitro.3×106 rat ovarian carcinoma cells NUTU19 were injected into the peritoneal cavity of F344 rat,paclitaxel nanoparticle and free paclitaxel were intraperitonealy administed to rats described above,tumor burden and ascite volumn were examined.HE staining,flow cytometry identified the antitumor effect of paclitaxel nanoparticle in vivo.Results:(1)The size of paclitaxel nanoparticle was 200nm,the entrapping efficiency was 70%.(2)Paclitaxel nanoparticle and free paclitaxel(cremophor) showed equivalent cytotoxic activity in vitro,the IC50 were 98.50±1.55ng/ml and 97.95±1.48ng/ml,respectively(P>0.05).(3)In rats implanted carcinoma cells,paclitaxel nanoparticles significantly reduced tumor weight and ascites [4.56±0.11g vs 10.13±0.52g(P<0.01);3.55±0.50ml vs 30.45±1.55ml(P<0.01)].(4) By HE staining,less mitosis was observed in paclitaxel nanoparticle group than in free paclitaxel group,tumor invasion to lymph nodes was seen in free paclitaxel group,which was not observed in paclitaxel nanoparticle group.(5) The incidences of tumor cells in G0/G1,G2/M and S phase in paclitaxel nanoparticle group were significantly different from that in free paclitaxel group[(93.35±1.25)% vs(87.31±1.32)%(P<0.05);(2.65±1.23)% vs(4.60±1.15)%(P<0.05);(4.00±1.15)% vs(8.09±1.20)%(P<0.05)].The apoptosis rate in paclitaxel nanoparticle group was much higher than that in the free paclitaxel group[(36.51±0.42)% vs(20.63±0.11)%(P<0.01)].Conclusion:The intraperitoneal administration of low-dose paclitaxel nanoparticle is safe,and can significantly inhibit the progression of ovarian carcinoma in peritoneal cavity of female F344 rat.

Primary study on the treatment of rat ovarian carcinoma via the intraperitoneal administration of paclitaxel nanoparticles